XNCR News and Press, Xencor Inc. From 02/07/23

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will present at the virtual 2023 SVB Securities Global Biopharma Conference on Tuesday...

Shares of Xencor (NASDAQ: XNCR) rose 12.6% this week as of Thursday afternoon, according to data provided by S&P Global Market Intelligence . The stock closed at $28.83 on Friday and then rose as high as $33.06 on Thursday. Xencor stock was up as high as 14.7% for the week before ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2023 corporate priorities and provided multiple clinical development updates. Bassil Dahiyat, Ph.D., presi...

Caris Life Sciences and Xencor Expand Target Discovery Collaboration for Novel XmAb® Antibody Drug Candidates PR Newswire IRVING, Texas and MONROVIA, Calif. , Jan. 5, 2023 /PRNewswire/ -- Caris Life Sciences ® (Caris), the leading molecular ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the 41 st Annual J.P. M...

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced additional clinical data from expansion cohorts in its Phase 1 study of plamotamab, a CD20 x CD3 bispecific a...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of data from the first patients in the Phase 2 combination study of vudalimab, a se...

Xencor, Inc. (XNCR) Q3 2022 Earnings Conference Call November 7, 2022 04:30 PM ET Company Participants Charles Liles - Head, Corporate Communications and IR Bassil Dahiyat - President & CEO John Kuch - CFO John Desjarlais - Chief Scientific Officer Al...

Xencor press release ( NASDAQ: XNCR ): Q3 GAAP EPS of -$0.55 beats by $0.13 . Revenue of $27.3M (+38.7% Y/Y) beats by $6.25M . Company expects to end 2022 with between $575 million and $600 million in cash, cash equivalents, receivables and marketable debt secu...

-- XmAb564, engineered IL-2 cytokine, is well-tolerated and generates a durable, dose-dependent and selective expansion of Tregs in single-dose, healthy volunteer study -- -- Management to host conference call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-s...